GENMAB AS DK 1/ DK0010272202 /
24/05/2024 14:08:17 | Chg. -15.600 | Volume | Bid14:24:51 | Ask14:24:51 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
256.300EUR | -5.74% | 279 Turnover: 72,116.300 |
256.200Bid Size: 120 | 256.300Ask Size: 120 | 16.93 bill.EUR | - | - |
GlobeNewswire
30/04
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03/04
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
17/10/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
25/09/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
04/09/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
19/10/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
20/09/2021
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
21/07/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021